Other

Blue Blood Biotech Corp.

Northwestern University

National Science Council

Kaohsiung Medical University

Shi, Guey-Yueh

Wu, Hua-Lin

Su, Hui-Pin

Chiang, Chuan-Chi

Lin, Shu-Wha

Wu, Karl

Hua-Lin Wu

Guey-Yueh Shi

Shu-Wha Lin

Chia-Ni Lin

Chih-Yuan Ma

Mei-Ling Ho

Jwu-Lai Yeh

Myron L Bender

Yi-Hsun Huang

Chao-Han Lai

Yi-Kai Hong

Huey-Chun Huang

Kuan-Chieh Wang

Tsung-Lin Cheng

Shu-Wa Lin

Chuan-Chi Chiang

Hui-Pin Su

The present application relates to dual anti-angiogenic and anti-inflammatory effects of recombinant thrombomodulin domain 1 (TMD1). Specifically, an isolated recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to TMD1 for use in treating an eye disease and/or an eye disorder associated with pathological ocular angiogenesis (POA) in a subject in need thereof is disclosed. The length of the recombinant polypeptide is no more than 200 amino acid residues. The eye disease and/or the eye disorder may be at least one selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Use of TMD1 in the manufacture of a medicament for treating an eye disease and/or an eye disorder associated with vascular endothelial growth factor (VEGF)-induced ocular angiogenesis and/or hypoxia-inducible factor-1&#x3b1; (HIF-1&#x3b1;)-VEGF pathway is also disclosed.

Recombinant thrombomodulin domain 1 for use in treating eye diseases associated with pathological ocular angiogenesis

A pharmaceutical composition for use in promoting wound healing and/or accelerating closure of an open wound in a subject in need thereof is disclosed. The composition comprises a therapeutically effective amount of a recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO: 2; and a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Composition for use in promoting wound healing

The present invention relates to a method for treating a bone loss disease, condition, or disorder in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a composition comprising thrombomodulin lectin-like domain (TMD1).

TMD1 protein for treating bone loss diseases

A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

Methods for treatment of CD14-mediated disorders and responses

A pharmaceutical composition comprising an effective amount of a mutant thrombomodulin is disclosed. The mutant thrombomodulin comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 2 and has residues corresponding to Alaand Alaof SEQ ID NO: 2. The mutant thrombomodulin has little or no protein C activation activity, and is effective in promoting wound healing and accelerating closure of an open wound in a diabetic.

Thrombomodulin variants and use thereof

A method for pharmacological prevention and suppression of aortic aneurysm development is disclosed. The method comprises administering a therapeutically effective amount of recombinant thrombomodulin to a subject in need thereof. The recombinant thrombomodulin prevents formation and/or retards progression of an aortic aneurysm.

Pharmacological treatment of aortic aneurysm development

The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for the use of accelerating wound healing, comprising a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin.

Method for treating wounds using an EGF-like domain of thrombomodulin

A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2.

Methods and compositions for treating ischemia

The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog thereof. The compound is applied to skin or mucosal surface of the patient. The invention also relates to a method of treating inflammation caused by suppressing secretion of TNF-&#x3b1;, IL-6, or MCP-1 from macrophage comprising administering a patient in need of such treatment a therapeutically effective amount of NADPH oxidase inhibitor.

Dextromethorphan-based method for treating acne

The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Recombinant human factor IX and use thereof

The present invention relates to a method for preventing or treating a cardiovascular disease.

Methods and compositions for preventing or treating cardiovascular disease

The invention relates to a composition for promoting angiogenesis, for controlling DNA synthesis of a cell, and for controlling chemotactic motility of a cell. The invention also relates to a method for treating ischemia diseases.

Methods and compositions for promoting angiogenesis

The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX having substitution of amino acid residue of SEQ ID NO: 7 at amino acid position selected from the group consisting of 86, 277, and 338 (exclude the circumstance of a single substitution at amino acid position 338) exhibits better clotting activity than recombinant wild type factor IX.

The present invention relates to compositions, kits and treating methods for the alteration cell-cell adhesion, transport, or permeation properties of tissues. The present invention also relates to the application of drug(s) or peptide(s), compound or gene delivery, DNA or RNA(i), cosmetic or therapeutic use of the compositions and kits.

Compositions, kits and treating methods for alteration cell-cell adhesion, transport, or permeation properties of tissues

Mutants of streptokinase in which one or more amino acid residues in the region of Pro58-Lys59-Ser60-Lys61 were replaced by other amino acids become better fibrinolytic agents. The mutants are resistant to the hydrolytic inactivation by plasmin and are more efficient in inducing fibrinolysis of plasma clots.

Growing community of inventors

Tainan, Taiwan

Hua-Lin Wu